Clinical Trial Update: A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation [EARLY_Phase 1]

View source ↗

Summary

A completed early-phase, single-center pilot study evaluating a preemptive short course of glecaprevir/pibrentasvir in hepatitis C–positive patients undergoing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Hepatitis C

Drugs mentioned

• Mavyret (glecaprevir/pibrentasvir)

Snippet

Sponsor: NYU Langone Health | Conditions: ESRD | EARLY_Phase 1 | Status: COMPLETED